Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea flag South Korea · Delayed Price · Currency is KRW
990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST

Enzychem Lifesciences Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-18,121-18,132-22,107-9,326-25,093-27,865
Depreciation & Amortization
2,8333,1363,4583,5122,3892,111
Loss (Gain) From Sale of Assets
126.48153.611.342010.9813.27
Asset Writedown & Restructuring Costs
3,7283,743145.5632.744,692-16.05
Loss (Gain) From Sale of Investments
16.8316.982,010-3.65-3.57-4.39
Loss (Gain) on Equity Investments
987.45770.192,176-26.8713.64445.14
Stock-Based Compensation
---54.33-306.12711.91
Provision & Write-off of Bad Debts
-325.56352.17-85.85199.23-111.7516.95
Other Operating Activities
3,3453,66111,0731,7857,3007,746
Change in Accounts Receivable
4,8513,6823,732-4,202-1,046-1,037
Change in Inventory
530.29234.972,832-4,574-1,439822.73
Change in Accounts Payable
-836.96-1,151-3,9794,392-333.721,703
Change in Unearned Revenue
---1.94110.39180.05
Change in Other Net Operating Assets
-7,745-7,479168.7-2,122-501.84-3,417
Operating Cash Flow
-10,610-11,012-573.93-10,258-14,320-18,589
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-548.42-762.68-323.82-2,248-7,957-5,818
Sale of Property, Plant & Equipment
49.1349.13--1.347.5
Cash Acquisitions
-100-100--577.53--
Divestitures
10.610.04----
Sale (Purchase) of Intangibles
40.48222.3-6.7-54.19-55.45-64.45
Sale (Purchase) of Real Estate
---158.69---
Investment in Securities
16,28419,28115,36362,350-93,370-3,665
Other Investing Activities
-2,330153.6-1,962-139.25-7,429-240.88
Investing Cash Flow
14,86811,9277,35953,562-109,233-9,729

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-3,1503,9832,55445,6717,140
Long-Term Debt Issued
-1,197-1,000--
Total Debt Issued
3,0804,3473,9833,55445,6717,140
Short-Term Debt Repaid
--3,560-2,853-25,640-26,991-6,420
Long-Term Debt Repaid
--1,127-2,446-12,666-43,889-1,559
Total Debt Repaid
-2,952-4,688-5,299-38,306-70,880-7,978
Net Debt Issued (Repaid)
127.66-340.55-1,316-34,752-25,210-838.54
Issuance of Common Stock
----153,71330,102
Repurchase of Common Stock
-977.08-3,004-10,822---
Other Financing Activities
00-0-1.2-00
Financing Cash Flow
-849.42-3,345-12,138-35,503128,50429,263

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
93.08-32.04186.64-13.79-83.1112.7
Miscellaneous Cash Flow Adjustments
---0--
Net Cash Flow
3,501-2,463-5,1667,7874,868958.31

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-11,159-11,775-897.74-12,506-22,277-24,407
Free Cash Flow Growth
------
Free Cash Flow Margin
-18.04%-17.38%-1.16%-16.45%-83.63%-106.23%
Free Cash Flow Per Share
-143.82-152.29-10.96-147.25-282.63-483.37
Levered Free Cash Flow
-1,991-3,106-4,554-13,645-32,617-22,543
Unlevered Free Cash Flow
-1,873-2,980-4,405-13,258-26,348-16,600

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
201.83210.92240.83478.22-174.26366.93
Cash Income Tax Paid
--251.58-317.1867.5176.3311.49
Change in Working Capital
-3,200-4,7132,754-6,504-3,210-1,748